Q-omics provides the consensus-scored STAB1 profile across patient tissues and cancer cell-line models. STAB1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, STAB1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, STAB1 protein abundance shows 34,589 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where STAB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAB1 survival associations across molecular data types. STAB1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAB1 RNA expression–survival associations across cancer types. High STAB1 expression shows unfavorable associations in KIRP, UVM and OV, but favorable associations in HNSC, LUAD and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for STAB1 RNA expression.
This table summarizes STAB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STAB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAB1 shows lower tumor expression in COAD, BLCA, BRCA and LUSC and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher STAB1 RNA expression in tumor versus normal tissue (log2 FC = +1.858, t-test p < 0.001).
This table shows molecular features associated with STAB1 in patient tissues and cancer cell lines. In patient samples, STAB1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, STAB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
